European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer

TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.